PMID- 35664030
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230916
IS  - 1895-5770 (Print)
IS  - 1897-4317 (Electronic)
IS  - 1895-5770 (Linking)
VI  - 17
IP  - 2
DP  - 2022
TI  - Histamine 2 receptor antagonists do not improve the outcomes of hospitalized 
      COVID-19 patients.
PG  - 146-151
LID - 10.5114/pg.2021.107799 [doi]
AB  - INTRODUCTION: Some observational studies have demonstrated the benefit of 
      famotidine in COVID-19-infected individuals. The preference of using an H(2) 
      receptor antagonist (H(2)RA) over proton pump inhibitors (PPI) during the 
      COVID-19 pandemic has been questioned by clinicians. AIM: To compare the outcomes 
      of hospitalized patients who were taking H(2)RA vs. PPI. MATERIAL AND METHODS: We 
      conducted a retrospective review of patients admitted for COVID-19 infection from 
      1 March until 31 July 2020. We included 396 patients admitted during the study 
      period. Of the total, 39 (9.8%) received H(2)RA and 86 (21.7%) were taking PPI as 
      home medications; 6 patients were taking both H(2)RA and PPI. RESULTS: The 
      baseline characteristics and comorbid conditions were similar in both groups. The 
      mean age was 57.79 +/-17.36 years, 43.2% were female, and 48.7% were Caucasian. The 
      common comorbid conditions included HTN (56.8%), obesity (44.4%), diabetes 
      mellitus (38.6%), and coronary artery disease (30.1%). Smoking was more prevalent 
      in the PPI group (42.5% vs. 18.2%, p = 0.03). Gastrointestinal symptoms were seen 
      on initial presentation in 31.1%, and 43.9% had elevated liver enzymes. The 
      H(2)RA group had similar mortality (HR = 0.84, 95% CI: 0.35-2.05) to the 
      non-H(2)B group. It remained non-significant as compared to PPI (HR = 0.34-3.19, 
      95% CI: 0.34-3.19). The secondary outcomes including readmission, ICU admission, 
      and severe COVID infections (including ARDS and thromboembolism) were similar in 
      these groups. CONCLUSIONS: The H(2) receptor antagonist used as a home medication 
      did not show benefit over the PPI in patients admitted for COVID-19 infections.
CI  - Copyright (c) 2022 Termedia.
FAU - Amjad, Waseem
AU  - Amjad W
AD  - Department of Internal Medicine, Albany Medical Center, Albany, NY, USA.
FAU - Kamal, Faisal
AU  - Kamal F
AD  - Department of Gastroenterology, University of Tennessee, Memphis, TN, USA.
FAU - Malik, Adnan
AU  - Malik A
AD  - Department of Internal Medicine, Loyola University Medical Center, Chicago, IL, 
      USA.
FAU - Singh, Ritu
AU  - Singh R
AD  - Department of Internal Medicine, University of Indiana, Fort Wayne, IN, USA.
AD  - Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
FAU - Mahmood, Sultan
AU  - Mahmood S
AD  - Department of Gastroenterology, University at Buffalo, Buffalo, NY, USA.
LA  - eng
PT  - Journal Article
DEP - 20210714
PL  - Poland
TA  - Prz Gastroenterol
JT  - Przeglad gastroenterologiczny
JID - 101280380
PMC - PMC9165339
OTO - NOTNLM
OT  - H2 receptor blocker
OT  - coronavirus disease 2019
OT  - proton pump inhibitors
COIS- The authors declare no conflict of interest.
EDAT- 2022/06/07 06:00
MHDA- 2022/06/07 06:01
PMCR- 2022/01/01
CRDT- 2022/06/06 14:08
PHST- 2021/04/12 00:00 [received]
PHST- 2021/06/01 00:00 [accepted]
PHST- 2022/06/06 14:08 [entrez]
PHST- 2022/06/07 06:00 [pubmed]
PHST- 2022/06/07 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 44707 [pii]
AID - 10.5114/pg.2021.107799 [doi]
PST - ppublish
SO  - Prz Gastroenterol. 2022;17(2):146-151. doi: 10.5114/pg.2021.107799. Epub 2021 Jul 
      14.